Compass's Psychedelic Drug Achieves Key Phase 3 Success in Depression Treatment
TL;DR Summary
Compass Pathways' psilocybin drug for treatment-resistant depression met its primary goal by reducing symptoms, but fell short of investor expectations, leading to a significant drop in stock price. The trial showed a modest 3.6-point improvement, with sustained benefits observed six weeks after a single dose, highlighting potential in psychedelic therapy for mental health treatment.
- Compass’s Psychedelic Drug to Treat Depression Meets Goal in Trial Yahoo Finance
- Compass Pathways’ Psilocybin Clears First Phase 3 Hurdle Psychedelic Alpha
- Compass points to psychedelic therapy's phase 3 depression win, but investors unimpressed Fierce Biotech
- Compass psilocybin therapy shown to be effective in largest-ever study in depression STAT
- Compass Plots Path to FDA With ‘Meaningful’ Phase III Data for Psilocybin Drug in Depression BioSpace
Reading Insights
Total Reads
0
Unique Readers
2
Time Saved
2 min
vs 3 min read
Condensed
87%
419 → 54 words
Want the full story? Read the original article
Read on Yahoo Finance